MX2021005936A - Metodos farmaceuticos. - Google Patents
Metodos farmaceuticos.Info
- Publication number
- MX2021005936A MX2021005936A MX2021005936A MX2021005936A MX2021005936A MX 2021005936 A MX2021005936 A MX 2021005936A MX 2021005936 A MX2021005936 A MX 2021005936A MX 2021005936 A MX2021005936 A MX 2021005936A MX 2021005936 A MX2021005936 A MX 2021005936A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical methods
- methods
- administering
- diseases
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000004243 Tubulin Human genes 0.000 abstract 1
- 108090000704 Tubulin Proteins 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770437P | 2018-11-21 | 2018-11-21 | |
| PCT/US2019/062494 WO2020106898A1 (en) | 2018-11-21 | 2019-11-20 | Pharmaceutical methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005936A true MX2021005936A (es) | 2021-08-24 |
Family
ID=70774631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005936A MX2021005936A (es) | 2018-11-21 | 2019-11-20 | Metodos farmaceuticos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230149377A1 (https=) |
| EP (1) | EP3883561A4 (https=) |
| JP (1) | JP2022507686A (https=) |
| KR (1) | KR20210099022A (https=) |
| AU (1) | AU2019384802A1 (https=) |
| CA (1) | CA3120366A1 (https=) |
| IL (1) | IL283273A (https=) |
| MX (1) | MX2021005936A (https=) |
| SG (1) | SG11202105221XA (https=) |
| TW (1) | TW202033189A (https=) |
| WO (1) | WO2020106898A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024137821A1 (en) * | 2022-12-21 | 2024-06-27 | Elevar Therapeutics, Inc. | Effect of rivoceranib on cytochrome p450 enzyme substrates |
| WO2025261988A1 (fr) * | 2024-06-17 | 2025-12-26 | Assistance Publique Hopitaux De Paris | Utilisation de nintédanib pour le traitement de la maladie de castleman |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| AU2013204181A1 (en) * | 2006-11-06 | 2013-05-16 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| CN101675930B (zh) * | 2008-09-16 | 2012-04-25 | 江苏恒瑞医药股份有限公司 | 用于治疗增生性疾病的药物组合物 |
| EP3141245A1 (en) * | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| CN106038566B (zh) * | 2016-06-10 | 2018-11-27 | 江阴市人民医院 | 一种用于胃癌治疗的药物组合物及其应用 |
| CN107669685A (zh) * | 2016-08-02 | 2018-02-09 | 江苏恒瑞医药股份有限公司 | 阿帕替尼与替加氟和紫杉类药物联合用于制备治疗胃癌的药物中的用途 |
-
2019
- 2019-11-20 CA CA3120366A patent/CA3120366A1/en active Pending
- 2019-11-20 JP JP2021527084A patent/JP2022507686A/ja active Pending
- 2019-11-20 WO PCT/US2019/062494 patent/WO2020106898A1/en not_active Ceased
- 2019-11-20 MX MX2021005936A patent/MX2021005936A/es unknown
- 2019-11-20 KR KR1020217018983A patent/KR20210099022A/ko not_active Abandoned
- 2019-11-20 SG SG11202105221XA patent/SG11202105221XA/en unknown
- 2019-11-20 TW TW108142221A patent/TW202033189A/zh unknown
- 2019-11-20 EP EP19887000.8A patent/EP3883561A4/en not_active Withdrawn
- 2019-11-20 US US17/295,848 patent/US20230149377A1/en not_active Abandoned
- 2019-11-20 AU AU2019384802A patent/AU2019384802A1/en not_active Abandoned
-
2021
- 2021-05-19 IL IL283273A patent/IL283273A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL283273A (en) | 2021-07-29 |
| KR20210099022A (ko) | 2021-08-11 |
| CA3120366A1 (en) | 2020-05-28 |
| US20230149377A1 (en) | 2023-05-18 |
| WO2020106898A1 (en) | 2020-05-28 |
| AU2019384802A1 (en) | 2021-06-17 |
| EP3883561A1 (en) | 2021-09-29 |
| EP3883561A4 (en) | 2022-07-27 |
| JP2022507686A (ja) | 2022-01-18 |
| SG11202105221XA (en) | 2021-06-29 |
| TW202033189A (zh) | 2020-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020014245A (es) | Inhibidores de quinasas dependientes de ciclinas. | |
| IL282727A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| ZA202204284B (en) | Inhibitors of raf kinases | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| CA2983481A1 (en) | Janus kinase inhibitor | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| MX2018007266A (es) | Combinaciones para el tratamiento del cancer. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| PH12021550413A1 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
| MX382778B (es) | Metodos para tratar cancer pancreatico | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| MX2021007477A (es) | Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer. | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
| MX2020005344A (es) | Compuestos de pirazolopiridinona. |